CM
NKGN

Crestline Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Crestline Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-76,000
Closed -$756K – 219
2022
Q4 		$756K Buy
+76,000
New +$751K 0.11% 130

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Crestline Management's NKGN Position: Q1 2023 in Review

Crestline Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2023, closing a stake of 76,000 shares — an estimated $756K sold.

Crestline Management first reported a position in NKGN in Q4 2022 and held it in 1 quarter. The position peaked at $756K in Q4 2022. 55 funds tracked by Wall St. Rank hold NKGN as of Q1 2023.

  • Crestline Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Crestline Management sold 76,000 NKGen Biotech, Inc. Common Stock shares in Q1 2023, an estimated $756K.
  • Crestline Management first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Crestline Management's NKGen Biotech, Inc. Common Stock position peaked at $756K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2023.

Based on Crestline Management's 13F filing for Q1 2023, filed 15 May 2023.